Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies the side effects of gemtuzumab ozogamicin and how well it works
in treating patients with acute myeloid leukemia. Monoclonal antibodies, such as gemtuzumab
ozogamicin, can block cancer growth in different ways. Some block the ability of cancer to
grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them